These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 33316313)

  • 21. Comparative risk of major cardiovascular events associated with second-line antidiabetic treatments: a retrospective cohort study using UK primary care data linked to hospitalization and mortality records.
    Zghebi SS; Steinke DT; Rutter MK; Emsley RA; Ashcroft DM
    Diabetes Obes Metab; 2016 Sep; 18(9):916-24. PubMed ID: 27177784
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Patterns of medication initiation in newly diagnosed diabetes mellitus: quality and cost implications.
    Desai NR; Shrank WH; Fischer MA; Avorn J; Liberman JN; Schneeweiss S; Pakes J; Brennan TA; Choudhry NK
    Am J Med; 2012 Mar; 125(3):302.e1-7. PubMed ID: 22340932
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of DPP-4 inhibitors and SGLT2 inhibitors compared to sulphonylureas in adult patients with diabetes with low c-peptide levels with or without anti-GAD65 antibody positivity.
    Sudan A; Kalra A; Mirza AA; Kant R
    Diabetes Metab Syndr; 2021; 15(4):102197. PubMed ID: 34245964
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Early glycaemic control in metformin users receiving their first add-on therapy: a population-based study of 4,734 people with type 2 diabetes.
    Thomsen RW; Baggesen LM; Søgaard M; Pedersen L; Nørrelund H; Buhl ES; Haase CL; Johnsen SP
    Diabetologia; 2015 Oct; 58(10):2247-53. PubMed ID: 26277380
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [About the choice between a DPP-4 inhibitor and a SGLT 2 inhibitor tor treating type 2 diabetes].
    Scheen AJ; Paquot N
    Rev Med Liege; 2016 Dec; 71(12):579-585. PubMed ID: 28387100
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Factors associated with the discontinuation of dipeptidyl peptidase-4 inhibitors (DPP-4is) after initiation of insulin.
    Fernandes G; Matos JE; Jaffe DH; Beyer G; Yang L; Iglay K; Gantz I; Rajpathak S
    Curr Med Res Opin; 2020 Mar; 36(3):377-386. PubMed ID: 31771370
    [No Abstract]   [Full Text] [Related]  

  • 27. A Review of Cardiovascular Outcomes Trials of Glucose-Lowering Therapies and Their Effects on Heart Failure Outcomes.
    Nassif ME; Kosiborod M
    Am J Cardiol; 2019 Dec; 124 Suppl 1():S12-S19. PubMed ID: 31741435
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intensification with dipeptidyl peptidase-4 inhibitor, insulin, or thiazolidinediones and risks of all-cause mortality, cardiovascular diseases, and severe hypoglycemia in patients on metformin-sulfonylurea dual therapy: A retrospective cohort study.
    Wong CKH; Man KKC; Shi M; Chan EW; Ho CW; Tse ETY; Wong ICK; Lam CLK
    PLoS Med; 2019 Dec; 16(12):e1002999. PubMed ID: 31877127
    [TBL] [Abstract][Full Text] [Related]  

  • 29. National Trends in Diabetes Medication Use in the United States: 2008 to 2015.
    Raval AD; Vyas A
    J Pharm Pract; 2020 Aug; 33(4):433-442. PubMed ID: 30572757
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Drugs for type 2 diabetes.
    Med Lett Drugs Ther; 2019 Nov; 61(1584):169-178. PubMed ID: 31770362
    [No Abstract]   [Full Text] [Related]  

  • 31. The association between diabetes medication and weight change in a non-surgical weight management intervention: an intervention cohort study.
    Aldekhail NM; Morrison DS; Khojah H; Sloan B; McLoone P; MacNaughton S; Shearer R; Logue J
    Diabet Med; 2020 Feb; 37(2):248-255. PubMed ID: 31365143
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dementia Diagnosis Is Associated with Changes in Antidiabetic Drug Prescription: An Open-Cohort Study of ∼130,000 Swedish Subjects over 14 Years.
    Secnik J; Xu H; Schwertner E; Hammar N; Alvarsson M; Winblad B; Eriksdotter M; Garcia-Ptacek S; Religa D
    J Alzheimers Dis; 2020; 76(4):1581-1594. PubMed ID: 32741836
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus.
    Raparelli V; Elharram M; Moura CS; Abrahamowicz M; Bernatsky S; Behlouli H; Pilote L
    J Am Heart Assoc; 2020 Jan; 9(1):e012940. PubMed ID: 31902326
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of antidiabetic agents on dementia risk: A Bayesian network meta-analysis.
    Zhou JB; Tang X; Han M; Yang J; Simó R
    Metabolism; 2020 Aug; 109():154265. PubMed ID: 32446679
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diabetes management and treatment approaches outside of North America and West Europe in 2006 and 2015.
    Tabesh M; Magliano DJ; Tanamas SK; Surmont F; Bahendeka S; Chiang CE; Elgart JF; Gagliardino JJ; Kalra S; Krishnamoorthy S; Luk A; Maegawa H; Motala AA; Pirie F; Ramachandran A; Tayeb K; Vikulova O; Wong J; Shaw JE
    Acta Diabetol; 2019 Aug; 56(8):889-897. PubMed ID: 30963308
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [New and old glucose lowering drugs; a state-of-the-art review].
    IJzerman RG; Vrijlandt PJWS
    Ned Tijdschr Geneeskd; 2020 Oct; 164():. PubMed ID: 33201636
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost Utility of Sodium-Glucose Cotransporter 2 Inhibitors in the Treatment of Metformin Monotherapy Failed Type 2 Diabetes Patients: A Systematic Review and Meta-Analysis.
    Bagepally BS; Gurav YK; Anothaisintawee T; Youngkong S; Chaikledkaew U; Thakkinstian A
    Value Health; 2019 Dec; 22(12):1458-1469. PubMed ID: 31806203
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differential cardiovascular outcomes after dipeptidyl peptidase-4 inhibitor, sulfonylurea, and pioglitazone therapy, all in combination with metformin, for type 2 diabetes: a population-based cohort study.
    Seong JM; Choi NK; Shin JY; Chang Y; Kim YJ; Lee J; Kim JY; Park BJ
    PLoS One; 2015; 10(5):e0124287. PubMed ID: 25992614
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predictors of medication adherence in patients with type 2 diabetes mellitus.
    Curkendall SM; Thomas N; Bell KF; Juneau PL; Weiss AJ
    Curr Med Res Opin; 2013 Oct; 29(10):1275-86. PubMed ID: 23815104
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of subgroups of patients with type 2 diabetes with differences in renal function preservation, comparing patients receiving sodium-glucose co-transporter-2 inhibitors with those receiving dipeptidyl peptidase-4 inhibitors, using a supervised machine-learning algorithm (PROFILE study): A retrospective analysis of a Japanese commercial medical database.
    Zhou FL; Watada H; Tajima Y; Berthelot M; Kang D; Esnault C; Shuto Y; Maegawa H; Koya D
    Diabetes Obes Metab; 2019 Aug; 21(8):1925-1934. PubMed ID: 31050099
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.